<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01492556</url>
  </required_header>
  <id_info>
    <org_study_id>CH-BC-015</org_study_id>
    <nct_id>NCT01492556</nct_id>
  </id_info>
  <brief_title>Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II, Single-arm, Multicenter Study of Etoposide Monotherapy in Treating Patients With Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital of the Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Putuo District Center Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Peace Maternity and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Etoposide Monotherapy is effective and safe
      in the treatment of recurrent or metastatic breast cancer in Chinese female patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current recommended dosage of Etoposide in treating breast cancer is 50 mg/m2 orally once a
      day for 21 days, repeated every 28 days. With retrospective data review, this study intends
      to adjust Etoposide dose to 60 mg/m2 daily for 10 days, repeated every 21 days as a cycle, to
      investigate the effectiveness and safety of Etoposide monotherapy in the treatment of
      recurrent or metastatic breast cancer in Chinese female patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response rate</measure>
    <time_frame>Every six weeks</time_frame>
    <description>Assessed by RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year survival rate</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Subjects will be followed from date of enrollment until the date of last visit, expected up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Every six weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etoposide Capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Lastet (Etoposide Capsules, 25mg*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.</description>
    <arm_group_label>Etoposide</arm_group_label>
    <other_name>Lastet, VP-16</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-80 years old.

          -  ECOG status: 0-2.

          -  Histologic or cytologic diagnosis of locally advanced or metastatic breast cancer.

          -  No more than three prior chemotherapies, adjuvant chemotherapy excluded.

          -  Received prior anthracycline, taxane therapy.

          -  At least 4 weeks from previous chemotherapy.

          -  Measurable disease of &gt;=2 cm (&gt;=1 cm on spiral CT scan).

          -  Life expectancy of ≥ 3 months.

          -  Adequate organ functions:

               -  Hemoglobin ≥10.0 g/dl, Absolute neutrophil count ≥1.5×10^9/L, Platelet count
                  ≥100×10^9/L,

               -  Creatinine clearance ≥60ml/min,

               -  Bilirubin ≤1.5 times upper limit of normal (ULN); AKP,AST and ALT ≤2.5x ULN(≤5x
                  ULN if due to liver metastases).

          -  Signed informed consent.

          -  Menopausal women or received surgical sterilization, women with children potential
             must not be pregnant or nursing with negative pregnancy test and willing to practice
             acceptable methods of birth control during the study and 3 months after the study.

        Exclusion Criteria:

          -  Pregnancy or lactation.

          -  Untreated or uncontrolled CNS metastases, or with refractory psychiatric illness.

          -  Prior treatment with Etoposide.

          -  Other primary malignancies within the past 5 years except for carcinoma in situ of the
             cervix or nonmelanoma skin cancer.

          -  Clinically significant heart diseases (e.g.congestive heart failure, symptomatic
             coronary disease, uncontrolled cardiac arrhythmia, Myocardial infarction) within the
             past 12 months.

          -  Serious uncontrolled concurrent infection or metabolism disorder.

          -  Concurrent treatment for active peptic ulcer disease or with digestive disorders.

          -  Prior radiotherapy and major surgery within 3 weeks before screening.

          -  Less than 4 weeks since prior investigational agents.

          -  Metastases present in more than one-third whole liver.

          -  Unable or unwilling to comply with the study protocol.

          -  Unsuitable to participate in study, that in the opinion of the treating physician.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binghe Xu, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Yuan, M.D.</last_name>
    <phone>86-10-8778-8114</phone>
    <email>yuanpeng01@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Hospital of the Ministry of Health</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Ding, MD</last_name>
      <phone>+86-13701314630</phone>
      <email>zhangygqg@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yongqiang Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Ding, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changjun Wang, MD</last_name>
      <phone>+86-10-6915-8936</phone>
      <email>wangchangjun.cannei@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Qiang Sun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Changjun Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Yu, MD</last_name>
      <phone>+86-13810292522</phone>
      <email>xiaoyugw@126.com</email>
    </contact>
    <investigator>
      <last_name>Dan Yu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guangyu An, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Yuan, M.D.</last_name>
      <phone>86-10-8778-8114</phone>
      <email>yuanpeng01@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Binghe Xu, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peng Yuan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donggui Wan, MD</last_name>
      <phone>+86-13601365686</phone>
      <email>dongguiwan@263.net</email>
    </contact>
    <investigator>
      <last_name>Liqun Jia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donggui Wan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Yan, MD</last_name>
      <phone>+86-13141316976</phone>
      <email>yan99640815@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Lijun Di, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ying Yan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangxi Cancer Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongxue Wang, MD</last_name>
      <phone>+86-13978806626</phone>
    </contact>
    <investigator>
      <last_name>Wei Wei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongxue Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang, MD</last_name>
      <phone>86-451-86298800</phone>
    </contact>
    <investigator>
      <last_name>Qingyuan Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yan, MD</last_name>
      <phone>+86-13673641112</phone>
      <email>ym200678@126.com</email>
    </contact>
    <investigator>
      <last_name>Shujun Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min Yan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiwei Gong, MD</last_name>
      <phone>+86-18941197930</phone>
      <email>gongweiwei12@163.com</email>
    </contact>
    <investigator>
      <last_name>Li Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weiwei Gong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>International Peace Maternity &amp; Child Health Hospital of the China Welfare Institute</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi He, MD</last_name>
      <phone>+86-13801858957</phone>
    </contact>
    <investigator>
      <last_name>Qi He, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Putuo District Center Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200062</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Zhu, MD</last_name>
      <phone>+86-13301679760</phone>
    </contact>
    <investigator>
      <last_name>Miaoqian Liang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qi Zhu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Cancer Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duo Ni, MD</last_name>
      <phone>+86-13909926820</phone>
    </contact>
    <investigator>
      <last_name>Duo Ni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jufen Cai, MD</last_name>
      <phone>+86-13867168680</phone>
      <email>CaiJf108@126.com</email>
    </contact>
    <investigator>
      <last_name>Jufen Cai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2011</study_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Binghe Xu</investigator_full_name>
    <investigator_title>Deputy Director of Department of Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>Recurrent</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

